Abstract:Background Glymphatic dysfunction is a crucial pathway for dementia. Alzheimer’s disease (AD) pathologies co-existing with cerebral small vessel disease (CSVD) is the most common pathogenesis for dementia. We hypothesize that AD pathologies and CSVD could be associated with glymphatic dysfunction, contributing to cognitive impairment. Method Participants completed with amyloid PET, diffusion tensor imaging (DTI), and T2 fluid-attenuated inversion-recovery (FLAIR) sequences were included from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). White matter hyperintensities (WMH), the most common CSVD marker, was evaluated from T2FLAIR images and represented the burden of CSVD. Amyloid PET was used to assess Aβ aggregation in the brain. We used diffusion tensor image analysis along the perivascular space (DTI-ALPS) index, the burden of enlarged perivascular spaces (PVS), and choroid plexus volume to reflect glymphatic function. The relationships between WMH burden/Aβ aggregation and these glymphatic markers as well as the correlations between glymphatic markers and cognitive function were investigated. Furthermore, we conducted mediation analyses to explore the potential mediating effects of glymphatic markers in the relationship between WMH burden/Aβ aggregation and cognition. Results One hundred and thirty-three participants along the AD continuum were included, consisting of 40 CN − , 48 CN + , 26 MCI + , and 19 AD + participants. Our findings revealed that there were negative associations between whole-brain Aβ aggregation ( r = − 0.249, p = 0.022) and WMH burden ( r = − 0.458, p < 0.001) with DTI-ALPS. Additionally, Aβ aggregation ( r = 0.223, p = 0.041) and WMH burden ( r = 0.294, p = 0.006) were both positively associated with choroid plexus volume. However, we did not observe significant correlations with PVS enlargement severity. DTI-ALPS was positively associated with memory ( r = 0.470, FDR- p < 0.001), executive function ( r = 0.358, FDR- p = 0.001), visual-spatial ( r = 0.223, FDR- p < 0.040), and language ( r = 0.419, FDR- p < 0.001). Conversely, choroid plexus volume showed negative correlations with memory ( r = − 0.315, FDR- p = 0.007), executive function ( r = − 0.321, FDR- p = 0.007), visual-spatial ( r = − 0.233, FDR- p = 0.031), and language ( r = − 0.261, FDR- p = 0.021). There were no significant correlations between PVS enlargement severity and cognitive performance. In the mediation analysis, we found that DTI-ALPS acted as a mediator in the relationship between WMH burden/Aβ accumulation and memory and language performances. Conclusion Our study provided evidence that both AD pathology (Aβ) and CSVD were associated with glymphatic dysfunction, which is further related to cognitive impairment. These results may provide a theoretical basis for new targets for treating AD.

Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From the ACT Autopsy Cohort.

Cerebral Amyloid Angiopathy and Neuritic Plaque Pathology Correlate with Cognitive Decline in Elderly Non-Demented Individuals.

O2‐03‐04: cerebral amyloid angiopathy correlates with cognitive decline in preclinical ad

Braak Stage, Cerebral Amyloid Angiopathy, and Cognitive Decline in Early Alzheimer’s Disease

The Relationship Between Amyloid Pathology, Cerebral Small Vessel Disease, Glymphatic Dysfunction, and Cognition: a Study Based on Alzheimer’s Disease Continuum Participants

Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration

Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease.

Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline

Using Neuroimaging to Study Cerebral Amyloid Angiopathy and Its Relationship to Alzheimer's Disease

The Association of Enlarged Perivascular Space with Microglia-Related Inflammation and Alzheimer's Pathology in Cognitively Normal Elderly

Differences in the cerebral amyloid angiopathy proteome in Alzheimer's disease and mild cognitive impairment

Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations

Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy - a cross-sectional study

Late-Life Blood Pressure and Cerebral Amyloid Angiopathy: Findings from the U.S. National Alzheimer's Coordinating Center Uniform Dataset

Abstract WMP14: Cerebrospinal Fluid Beta-Amyloid Concentration and MRI Manifestations of Cerebral Amyloid Angiopathy

Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis

Age-related macular degeneration is associated with probable cerebral amyloid angiopathy: A case-control study

Cognition Mediates the Association Between Cerebrospinal Fluid Biomarkers of Amyloid and P-Tau and Neuropsychiatric Symptoms

Subcortical volumes in cerebral amyloid angiopathy compared with Alzheimer's disease and controls

Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology

Abstract WP555: Plasma Beta-Secretase 1 in Cerebral Amyloid Angiopathy